WEKO3
アイテム
{"_buckets": {"deposit": "4b41a289-8311-47b1-9538-9e29471ddb26"}, "_deposit": {"created_by": 1, "id": "476", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "476"}, "status": "published"}, "_oai": {"id": "oai:showa.repo.nii.ac.jp:00000476", "sets": ["58"]}, "author_link": ["2254", "2255", "2256", "2253", "2257", "2252", "2258", "2259"], "item_10002_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "315", "bibliographicPageStart": "309", "bibliographicVolumeNumber": "30", "bibliographic_titles": [{"bibliographic_title": "The Showa University journal of medical sciences"}]}]}, "item_10002_description_6": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The safety and efficacy profiles of alectinib versus crizotinib for patients with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer still remains to be elucidated. We compared the overall efficacies of alectinib and crizotinib for previously untreated ALK-positive advanced non-small cell lung cancer through a meta-analysis of randomized controlled trials. The primary outcome was progression-free survival (PFS). Pooled estimates were calculated as hazard ratios with 95% confidence intervals. Two studies on alectinib met the inclusion criteria for this meta-analysis. The hazard ratio (95% confidence interval) of alectinib for PFS, relative to crizotinib, was 0.41 (0.28-0.60), demonstrating a superior overall efficacy of alectinib over crizotinib, in terms of PFS.", "subitem_description_type": "Abstract"}]}, "item_10002_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Showa University Society"}]}, "item_10002_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.15369/sujms.30.309", "subitem_relation_type_select": "DOI"}}]}, "item_10002_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AA10781651", "subitem_source_identifier_type": "NCID"}]}, "item_10002_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0915-6380 ", "subitem_source_identifier_type": "ISSN"}]}, "item_10002_text_26": {"attribute_name": "アイテムタイプ", "attribute_value_mlt": [{"subitem_text_value": "学内発行雑誌 / Departmental Bulletin Paper"}]}, "item_10002_text_27": {"attribute_name": "POS_INDEX", "attribute_value_mlt": [{"subitem_text_value": "学内発行雑誌/The Showa University journal of medical sciences/Vol.30(2018)/No.2"}]}, "item_10002_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "MANABE, Ryo"}], "nameIdentifiers": [{"nameIdentifier": "2252", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "ANDO, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "2253", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KUSUMOTO, Sojiro"}], "nameIdentifiers": [{"nameIdentifier": "2254", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "TANAKA, Akihiko"}], "nameIdentifiers": [{"nameIdentifier": "2255", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YAMAOKA, Toshimitsu"}], "nameIdentifiers": [{"nameIdentifier": "2256", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OHMORI, Tohru"}], "nameIdentifiers": [{"nameIdentifier": "2257", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OHNISHI, Tsukasa"}], "nameIdentifiers": [{"nameIdentifier": "2258", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "SAGARA, Hironori"}], "nameIdentifiers": [{"nameIdentifier": "2259", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-07-26"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "S30_309.pdf", "filesize": [{"value": "427.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 427100.0, "url": {"label": "S30_309.pdf", "url": "https://showa.repo.nii.ac.jp/record/476/files/S30_309.pdf"}, "version_id": "6012a8e1-7db1-44a4-8975-b9e2e6319106"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis", "subitem_title_language": "en"}]}, "item_type_id": "10002", "owner": "1", "path": ["58"], "permalink_uri": "https://showa.repo.nii.ac.jp/records/476", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-09-05"}, "publish_date": "2018-09-05", "publish_status": "0", "recid": "476", "relation": {}, "relation_version_is_last": true, "title": ["Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis"], "weko_shared_id": 1}
Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis
https://showa.repo.nii.ac.jp/records/476
https://showa.repo.nii.ac.jp/records/476efbea144-0d4f-418f-8197-efb9d8bd3be9
名前 / ファイル | ライセンス | アクション |
---|---|---|
S30_309.pdf (427.1 kB)
|
|
Item type | 学内発行雑誌 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-09-05 | |||||
タイトル | ||||||
タイトル | Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ | departmental bulletin paper | |||||
著者 |
MANABE, Ryo
× MANABE, Ryo× ANDO, Koichi× KUSUMOTO, Sojiro× TANAKA, Akihiko× YAMAOKA, Toshimitsu× OHMORI, Tohru× OHNISHI, Tsukasa× SAGARA, Hironori |
|||||
書誌情報 |
The Showa University journal of medical sciences 巻 30, 号 2, p. 309-315, 発行日 2018-06 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The safety and efficacy profiles of alectinib versus crizotinib for patients with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer still remains to be elucidated. We compared the overall efficacies of alectinib and crizotinib for previously untreated ALK-positive advanced non-small cell lung cancer through a meta-analysis of randomized controlled trials. The primary outcome was progression-free survival (PFS). Pooled estimates were calculated as hazard ratios with 95% confidence intervals. Two studies on alectinib met the inclusion criteria for this meta-analysis. The hazard ratio (95% confidence interval) of alectinib for PFS, relative to crizotinib, was 0.41 (0.28-0.60), demonstrating a superior overall efficacy of alectinib over crizotinib, in terms of PFS. | |||||
DOI | ||||||
関連識別子 | 10.15369/sujms.30.309 | |||||
出版者 | ||||||
出版者 | Showa University Society | |||||
ISSN | ||||||
収録物識別子 | 0915-6380 | |||||
著者版フラグ | ||||||
出版タイプ | VoR |